Engineered immune cells take on tough lupus cases

NCT ID NCT06333483

Recruiting now Disease control Sponsor: Autolus Limited Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated Apr 23, 2026 · Updated 16 times

Summary

This early-stage study tests a treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't responded to other therapies. Obe-cel uses a patient's own immune cells, modified to target and destroy faulty B cells that drive lupus. The main goals are to check safety and see if it can put lupus into remission. About 18 adults and teens will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Addenbrookes Hospital
RECRUITING

Cambridge, CB2 0QQ, United Kingdom

Contact Email: •••••@•••••
Great Ormond Street Hospital
RECRUITING

London, WC1N 3JH, United Kingdom

Contact Email: •••••@•••••
Hospital Universitari Vall Hebrón
RECRUITING

Barcelona, 08035, Spain

Contact Email: •••••@•••••
Hospital Universitari i Politecnic La Fe
RECRUITING

Valencia, 106046026, Spain

Contact Email: •••••@•••••
Manchester Royal Infirmary, Manchester University NHS Foundation Trust,
RECRUITING

Manchester, M13 9WL, United Kingdom

Contact Email: •••••@•••••
University College London Hospitals NHS Foundation Trust
RECRUITING

London, NW1 2PG, United Kingdom

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS